<?xml version='1.0' encoding='utf-8'?>
<document id="32150643"><sentence text="A Simple Methodology to Differentiate Changes in Bioavailability from Changes in Clearance Following Oral Dosing of Metabolized Drugs." /><sentence text="Accurately discriminating changes in clearance (CL ) from changes in bioavailability (F ) following an oral drug-drug interaction is difficult without carrying out an IV interaction study" /><sentence text=" This may be true for drugs that are clinically-significant transporter substrates, however, for interactions that are strictly metabolic it has been recognized that volume of distribution remains unchanged between both phases of the interaction study" /><sentence text=" With the understanding that changes in volume of distribution will be minimal for metabolized drugs, the inverse of the change in apparent volume of distribution (Vss /F) can provide adequate estimates of the change in bioavailability alone" /><sentence text=" Utilization of this estimate of F change in tandem with the observed apparent clearance (CL/F) change in an oral drug-drug interaction can provide an estimate of the change in clearance alone"><entity charOffset="33-34" id="DDI-PubMed.32150643.s5.e0" text="F" /><entity charOffset="93-93" id="DDI-PubMed.32150643.s5.e1" text="F" /><pair ddi="false" e1="DDI-PubMed.32150643.s5.e0" e2="DDI-PubMed.32150643.s5.e0" /><pair ddi="false" e1="DDI-PubMed.32150643.s5.e0" e2="DDI-PubMed.32150643.s5.e1" /></sentence><sentence text=" Here, we examine drug-drug interactions involving 5 known inhibitors and inducers of CYP3A4 on victim drugs midazolam and apixaban for which the interaction was carried out both orally and intravenously, allowing for evaluation of this methodology"><entity charOffset="123-131" id="DDI-PubMed.32150643.s6.e0" text="apixaban" /></sentence><sentence text=" Predictions of CL and F changes based on oral data were reasonably close to observed changes based on intravenous studies, demonstrating that this simple yet powerful methodology can reasonably differentiate changes in F from changes in CL for oral metabolic drug interactions when only oral data are available"><entity charOffset="220-221" id="DDI-PubMed.32150643.s7.e0" text="F" /><entity charOffset="23-23" id="DDI-PubMed.32150643.s7.e1" text="F" /><pair ddi="false" e1="DDI-PubMed.32150643.s7.e1" e2="DDI-PubMed.32150643.s7.e1" /><pair ddi="false" e1="DDI-PubMed.32150643.s7.e1" e2="DDI-PubMed.32150643.s7.e0" /></sentence><sentence text=" Utilization of this relatively simple methodology to evaluate DDIs for orally dosed drugs will have a significant impact on how DDIs are interpreted from a drug development and regulatory perspective" /><sentence text="" /></document>